<DOC>
	<DOCNO>NCT03057743</DOCNO>
	<brief_summary>Pilot study use [ 18F ] ISO-1 PET/CT image sigma-2 receptor bind metastatic breast cancer . Correlate baseline uptake change uptake therapy time progression standard experimental pathology assay biopsy surgical tissue . The target population 30 adult patient least 18 year , least one site disease outside liver least one type standard imaging .</brief_summary>
	<brief_title>Imaging Vivo Sigma-2 Receptor Expression With 18F-ISO-1 Positron Emission Tomography Metastatic Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<criteria>At least 18 year age Biopsy proven clinically document metastatic breast cancer least one lesion outside liver standard imaging ( e.g . CT , MRI , Bone Scan , Ultrasound , FDG PET/CT ) Plan start new systemic therapy metastatic disease . Participants must inform investigational nature study willing provide write informed consent participate study accordance institutional federal guideline prior studyspecific procedure . Females pregnant time screen eligible study , urine serum pregnancy test perform woman childbearing potential time screen . Inability tolerate image procedure opinion investigator treat physician . Serious unstable medical psychological condition , opinion investigator , would compromise subject 's safety successful participation study .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>